I agree and don't really understand why.
One of the CEO's roles is to manage shareholder's expectations. By going radio silent on this issue Doc S has missed an opportunity to quell the doubts of shareholders. There have clearly been issues with scale-up because otherwise I believe TOX would've been started by now.
Ebola is a serious issue for the world at large. However ability to manufacture viricides in the quantities necessary to perform Tox is the NNVC issue at large...if the company cannot produce enough of the cides for regulatory studies why should I believe they can produce sufficient quantities of the cides to treat a burgeoning Ebola epidemic?
They can't do an end-run around Tox, and the Mers hype is reminiscent of Ebola, or is that backwards?
What happened to MERs and PHE again? Oh don't know cause there's been radio silence from Management.
Another relevant question is, will there be an investors call with the release of the 10-k?
L Vus feel free to include any of these questions, although you may want to adjust the tone.
In case it's not clear, where the hell are the Tox studies???
News 
Market Data 
Discover 
